Core Viewpoint - The announcement by Zhifei Biological indicates a significant breakthrough in the treatment of metabolic diseases, specifically with the completion of Phase III clinical trials for the CA508 insulin injection, which lays the groundwork for future market approval [1] Group 1: Clinical Trial Results - The CA508 injection, developed by the subsidiary Chuanan Biological, has completed Phase III clinical trials and received a summary report, marking a key milestone for the company in the diabetes treatment sector [1] - The clinical trial was led by Peking University People's Hospital and involved 40 domestic research centers, focusing on Type 2 diabetes patients with inadequate insulin treatment [1] - Results show that CA508 injection is comparable in efficacy and safety to the original drug (NovoRapid®), meeting relevant guidelines and providing core evidence for registration [1] Group 2: Product Details - CA508 injection is a new generation of basal-bolus insulin formulation, combining degludec insulin and aspart insulin, which allows for dual control of basal and postprandial blood glucose levels [1] - The formulation is a clear solution that requires 1-2 daily injections without the need for mixing, enhancing patient compliance [1] Group 3: Market Implications - Currently, there is only one other similar product approved in the domestic market aside from the original drug, indicating a potential competitive advantage for CA508 if approved [1] - The successful launch of CA508 injection would further solidify the company's integrated "prevention & treatment" strategy, strengthening its market position and industry competitiveness [1]

Core Viewpoint - Chongqing Zhifei Biological Products Co., Ltd. has achieved a significant breakthrough in the treatment of metabolic diseases with the successful completion of Phase III clinical trials for its CA508 injection, paving the way for future product registration [1][2]. Group 1: Product Development - The CA508 injection is a new generation of dual insulin formulation, combining long-acting insulin (degludec) and rapid-acting insulin (aspart), which allows for precise control of both baseline and postprandial blood sugar levels while significantly reducing the risk of hypoglycemia [2]. - The formulation is designed for ease of use, requiring only 1-2 injections per day without the need for mixing prior to use, thereby improving patient compliance [2]. Group 2: Clinical Trial Details - The Phase III clinical trial was led by Peking University People's Hospital and involved 40 research centers across China, employing a multi-center, randomized, open-label, parallel-controlled design [2]. - The trial focused on type 2 diabetes patients who had poor blood sugar control after previous treatment with basal or premixed insulin, addressing an unmet clinical need [2]. - The clinical trial summary report indicates that CA508 injection's efficacy and safety are comparable to the original drug, providing a solid basis for subsequent registration applications [2]. Group 3: Market Landscape - As of the announcement date, only one other company has a similar product approved in the domestic market, positioning CA508 injection as a promising local innovative treatment option for type 2 diabetes patients [3]. - Zhifei Biological aims to accelerate the transformation of research results into practical applications, guided by public health needs [3].